HENRIQUE BARBOSA RIBEIRO

Índice h a partir de 2011
20
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Mostrar mais
Limpar filtros

Configurações

Colaboração internacional: Estados Unidos ×

Resultados de Busca

Agora exibindo 1 - 10 de 43
  • article 7 Citação(ões) na Scopus
    Long Term Follow-Up of Drug Eluting Versus Bare Metal Stents in the Treatment of Saphenous Vein Graft Lesions
    (2013) YBARRA, Luiz F.; RIBEIRO, Henrique B.; POZETTI, Antonio H.; CAMPOS, Carlos A.; ESPER, Rodrigo B.; LEMOS, Pedro A.; LOPES, Augusto C.; KALIL-FILHO, Roberto; ELLIS, Stephen G.; RIBEIRO, Expedito E.
    Introduction: The safety and effectiveness of drug-eluting stent (DES) compared with bare metal stents (BMS) for the treatment of saphenous vein graft (SVG) disease is controversial, especially because of the lack of long-term follow-up. The aim of this study was to address the late outcome of DES versus BMS for the treatment of SVG lesions. Methods: A matched, case-control study included 82 patients in each group. Patients groups were matched by gender, age, clinical presentation, and diabetes. The primary study end point was occurrence of major adverse cardiovascular events (MACE). Secondary end points included death, cardiac death, myocardial infarction (MI), and target vessel revascularization (TVR). Results: Clinical and angiographic characteristics were similar between the groups. At 6 months, TVR (hazard ratio [HR] 6.12, 95% confidence interval [CI] 1.39 to 26.93, P = 0.05), and MACE (HR 2.54, 95% CI 1.08 to 5.98, P = 0.04) were higher in the BMS group. At 4 years the risks of MI (P = 0.21), TVR (P = 0.99), and MACE (P = 0.21) were similar between both groups. However, the rates of death (HR 2.74, 95% CI 1.11 to 6.74, P = 0.04) and cardiac death (HR 4.26, 95% CI 1.59 to 11.35, P = 0.01) were significantly higher in the BMS group. Conclusions: These results suggest that the use of DES compared with BMS in the treatment of SVG lesions reduces TVR and MACE at 6 months of follow-up, a benefit that was lost over the next 3-4 years. (C) 2012 Wiley Periodicals, Inc.
  • conferenceObject
    IMPACT OF MORBID OBESITY AND OBESITY PHENOTYPE ON OUTCOMES POST TRANSCATHETER AORTIC VALVE REPLACEMENT
    (2020) MCINERNEY, A.; TIRADO-CONTE, G.; RODES-CABAU, J.; CAMPELO-PARADA, F.; SOTO, J. D. Tafur; BARBANTI, M.; MUNOZ-GARCIA, E.; ARIF, M.; LOPEZ, D.; TOGGWEILER, S.; VEIGA, G.; PYLKO, A.; SEVILLA, T.; COMPAGNONE, M.; REGUEIRO, A.; SERRA, V.; CARNERO, M.; OTEO, J. F.; RIVERO, F.; RIBEIRO, H. Barbosa; GUIMARAES, L.; MATTA, A.; ECHAVARRIA, N. Giraldo; VALVO, R.; MOCCETTI, F.; MUNOZ-GARCIA, A. J.; LOPEZ-PAIS, J.; BLANCO, B. Garcia del; BORGES, D. Carter Campanha; GONZALO, N.; DUMONT, E.; CRISCIONE, E.; DABROWSKI, M.; ALFONSO, F.; HERNANDEZ, J. M. de la Torre; CHEEMA, A. N.; AMAT-SANTOS, I.; SAIA, F.; ESCANED, J.; NOMBELA-FRANCO, L.
  • article 0 Citação(ões) na Scopus
    Left ventricular global longitudinal strain assessment in patients with takotsubo cardiomyopathy : a call for an echocardiography-based classification
    (2022) REDDIN, Gemma; FORRESTAL, Brian J.; GARCIA-GARCIA, Hector M.; MEDVEDOFSKY, Diego; SINGH, Manavotam; ASCH, Federico M.; RIBEIRO, Henrique B.; CAMPOS, Carlos M.
    BACKGROUND: Takotsubo cardiomyopathy (TTC) is classified into 4 types depending on the anatomical area affected identified on gross visual assessment. We have sought to understand if it is feasible and advantageous to use left ventricular global longitudinal strain (LVGLS), LV segmental longitudinal strain and right ventricle free wall strain (RVFWS) to classify TTC. METHODS: We conducted a retrospective observational study on twenty-five patients who meet the Modified Mayo Clinic Criteria for TTC [1]. Two independent reviewers performed strain analysis, they were both blinded to patient???s diagnosed classification and outcomes. RESULTS: Based on classification by traditional assessment the 92% (N.=23) were diagnosed with typical TTC, indicating apical involvement. The entire LV was affected, 67% (N.=16) had abnormal strain (STE>-18) in all three LV regions (base, mid-ventricle and apex). Seventy-one percent of patients (N.=17) had abnormal LVGLS (>-18). Abnormal strain across all three LV regions was associated with higher prevalence (70%, N.=8 Vs 30%, N.=4, respectively) of composite cardiovascular events and longer length of hospital stay. There was a statistically significant difference in average length of hospital stay in those patients who had abnormal strain in all three regions compared to those that did not have abnormal strain across all three regions (8 days compared to 3.44 days, P=0.02). CONCLUSIONS: A new classification of TCC based on strain analysis should be developed. The traditional model is arbitrary; it fails to recognize that in most patients the entire LV is affect, it does not have prognostic significance and the most prevalent typical variant indicates apical involvement. Our study suggests that the entire LV is affected, and strain analysis has prognostic significance. (Cite this article as: Reddin G, Forrestal BJ, Garcia-Garcia HM, Medvedofsky D, Singh M, Asch FM, et al. Left ventricular global longitudinal strain assessment in patients with takotsubo cardiomyopathy: a call for an echocardiography-based classification. Minerva Cardiol Angiol 2022;70:321-8. DOI: 10.23736/S2724-5683.20.05386-4)
  • article 0 Citação(ões) na Scopus
    Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials
    (2023) RAVANI, Lis Victoria; GEWEHR, Douglas Mesadri; CALOMENI, Pedro; GAUZA, Mateus de Miranda; PEREIRA, Jussara; CARDOSO, Rhanderson; RIBEIRO, Henrique Barbosa; BOCCHI, Edimar
    Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) associated (HF). However, its association with improved atherosclerotic cardiovascular disease (ASCVD) events remains unclear. We performed a meta-analysis to evaluate the associaangiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in terms of myocardial infarction, stroke, angina pectoris, peripheral artery disease, and the composite end point in patients with HF. A total of 8 randomized controlled trials were included, with 17,541 patients assigned to either the ARNI (8,764 patients) or ACEi/ARB (8,777 patients) groups. The incidence of composite end point (risk ratio [RR] 1.03, 95% confidence interval [CI] 0.93 to 1.13, p = 0.63), myocardial infarction (RR 1.02, 95% CI 0.81 to 1.30, p = 0.85), angina pectoris (RR 0.96, 95% CI 0.80 to 1.17, p = 0.70), and stroke (RR 0.99, 95% CI 0.85 to 1.16, p = 0.93) were not statistically different between the ARNI and ACEi/ARB groups. However, ARNI was associated with a higher incidence of peripheral artery disease (RR 1.63, 95% CI 1.05 to 2.52, p = 0.03). In conclusion, this meta-analysis found no association between ARNI therapy and improved ASCVD events in patients with HF. & COPY; 2023 Elsevier Inc. All rights reserved. (Am J Cardiol 2023;205:259-268)
  • article 15 Citação(ões) na Scopus
    Novel device-based therapies to improve outcome in ST-segment elevation myocardial infarction
    (2021) MARIA, Giovanni Luigi De; GARCIA-GARCIA, Hector M.; SCARSINI, Roberto; FINN, Aloke; SATO, Yu; VIRMANI, Renu; BHINDI, Ravinay; CIOFANI, Jonathan L.; NUCHE, Jorge; RIBEIRO, Henrique B.; MATHIAS JR., Wilson; YERASI, Charan; FISCHELL, Tim A.; OTTERSPOOR, Luuk; RIBICHINI, Flavio; IBANEZ, Borja; PIJLS, Nico H. J.; SCHWARTZ, Robert S.; KAPUR, Navin K.; STONE, Gregg W.; BANNING, Adrian P.
    Primary percutaneous coronary intervention (PPCI) has dramatically changed the outcome of patients with ST-elevation myocardial infarction (STEMI). However, despite improvements in interventional technology, registry data show little recent change in the prognosis of patients who survive STEMI, with a significant incidence of cardiogenic shock, heart failure, and cardiac death. Despite a technically successful PPCI procedure, a variable proportion of patients experience suboptimal myocardial reperfusion. Large infarct size and coronary microvascular injury, as the consequence of ischaemia-reperfusion injury and distal embolization of atherothrombotic debris, account for suboptimal long-term prognosis of STEMI patients. In order to address this unmet therapeutic need, a broad-range of device-based treatments has been developed. These device-based therapies can be categorized according to the pathophysiological pathways they target: (i) techniques to prevent distal atherothrombotic embolization, (ii) techniques to prevent or mitigate ischaemia/reperfusion injury, and (iii) techniques to enhance coronary microvascular function/integrity. This review is an overview of these novel technologies with a focus on their pathophysiological background, procedural details, available evidence, and with a critical perspective about their potential future implementation in the clinical care of STEMI patients.
  • article 27 Citação(ões) na Scopus
    Valve-in-Valve Challenges: How to Avoid Coronary Obstruction
    (2019) BERNARDI, Fernando L. M.; DVIR, Danny; RODES-CABAU, Josep; RIBEIRO, Henrique B.
    Coronary obstruction is a rare but life-threatening complication in patients undergoing transcatheter aortic valve replacement (TAVR). Aortic valve-in-valve (VIV) procedures to treat failed surgical bioprosthesis is associated with similar to 6-fold higher risk for coronary obstruction in certain situations. The primary mechanism consists in the occlusion of the coronary ostium by the dislodged leaflet from the bioprosthesis after deployment of the transcatheter heart valve (THV), which most commonly occurs during the index procedure, but in up to 1/3 of cases a delayed presentation ensues. The clinical presentation consists of severe hypotension and ECG changes in most of the patients, with very high mortality rates. Therefore, pre-procedural multi-slice computed tomography is crucial for identifying high-risk features, such as low coronary heights, shallow sinuses of Valsalva, and short virtual THV to coronary ostial distance (VTC). Also, some models of surgical bioprosthesis present an increased risk for this dreadful complication. Preemptive protective strategies with coronary wiring, with or without placement of an undeployed stent, could mitigate the risks associated with this complication in high-risk patients, even though studies are lacking. This review aims to take a clinical perspective on the challenges in avoiding this complication during VIV procedures.
  • article 72 Citação(ões) na Scopus
    Evaluation of current practices in transcatheter aortic valve implantation: The WRITTEN (WoRldwIde TAVI ExperieNce) survey
    (2017) CERRATO, Enrico; NOMBELA-FRANCO, Luis; NAZIF, Tamim M.; ELTCHANINOFF, Helene; SONDERGAARD, Lars; RIBEIRO, Henrique B.; BARBANTI, Marco; NIETLISPACH, Fabian; JAEGERE, Peter De; AGOSTONI, Pierfrancesco; TRILLO, Ramiro; JIMENEZ-QUEVEDO, Pilar; D'ASCENZO, Fabrizio; WENDLER, Olaf; MALUENDA, Gabriel; CHEN, Mao; TAMBURINO, Corrado; MACAYA, Carlos; LEON, Martin B.; RODES-CABAU, Josep
    Background: Transcatheter aortic valve implantation (TAVI) has been adopted worldwide as the standard treatment for severe aortic stenosis in symptomatic patients at prohibitive or high surgical risk, but there are still several areaswhere consensus and evidence are lacking. The purposewas to obtain a global view of current practice related to TAVI with the potential to identify the main areas of consensus and divergence between centers. Methods: An online questionnaire was distributed in centers performing TAVI including a total of 59 questions concerning pre-procedural evaluation, procedural practices and post-procedural management. Results: The survey was completed by 250 centers (with a cumulative experience of nearly 70,000 TAVI) from 38 different countries. Heart team meetings and surgical risk scores were routinely performed inmost (N95%) centers, but frailty (44%) and quality of life (28%) assessments were less frequently performed. General anesthesia remained the most frequent type of anesthesia (60% of centers), and significant variability was detected in the examinations for residual aortic regurgitation assessment during the procedure and in post-procedural ECG monitoring and temporary pacemaker implementation (from none to >= 72 h post-TAVI). Dual antiplatelet therapy duration post-TAVI was highly variable (1, 3, and >= 6 months in 14%, 41% and 32% of centers, respectively) and lack of consensus in antithrombotic regimen was observed in patients with atrial fibrillation requiring anticoagulation therapy (anticoagulation alone, anticoagulation + aspirin, anticoagulation + clopidogrel, and triple therapy in 28%, 37%, 26% and 4% of centers, respectively). Conclusions: The WRITTEN survey provided extensive data on current TAVI-related practice and identified important differences between centers in key aspects of pre-, intra-, and post-operative management. This highlights the urgent need for further studies and evidence-based data to guide multiple aspects of the TAVI field.
  • article 103 Citação(ões) na Scopus
    Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement Comprehensive Midterm Evaluation of Valve-in-Valve and Valve-in-Ring Implantation From the VIVID Registry
    (2021) SIMONATO, Matheus; WHISENANT, Brian; RIBEIRO, Henrique Barbosa; WEBB, John G.; KORNOWSKI, Ran; GUERRERO, Mayra; WIJEYSUNDERA, Harindra; SONDERGAARD, Lars; BACKER, Ole De; VILLABLANCA, Pedro; RIHAL, Charanjit; ELEID, Mackram; KEMPFERT, Jorg; UNBEHAUN, Axel; ERLEBACH, Magdalena; CASSELMAN, Filip; ADAM, Matti; MONTORFANO, Matteo; ANCONA, Marco; SAIA, Francesco; UBBEN, Timm; MEINCKE, Felix; NAPODANO, Massimo; CODNER, Pablo; SCHOFER, Joachim; PELLETIER, Marc; CHEUNG, Anson; SHUVY, Mony; PALMA, Jose Honorio; GAIA, Diego Felipe; DUNCAN, Alison; HILDICK-SMITH, David; VEULEMANS, Verena; SINNING, Jan-Malte; ARBEL, Yaron; TESTA, Luca; WEGER, Arend de; ELTCHANINOFF, Helene; HEMERY, Thibault; LANDES, Uri; TCHETCHE, Didier; DUMONTEIL, Nicolas; RODES-CABAU, Josep; KIM, Won-Keun; SPARGIAS, Konstantinos; KOURKOVELI, Panagiota; BEN-YEHUDA, Ori; TELES, Rui Campante; BARBANTI, Marco; FIORINA, Claudia; THUKKANI, Arun; MACKENSEN, G. Burkhard; JONES, Noah; PRESBITERO, Patrizia; PETRONIO, Anna Sonia; ALLALI, Abdelhakim; CHAMPAGNAC, Didier; BLEIZIFFER, Sabine; RUDOLPH, Tanja; IADANZA, Alessandro; SALIZZONI, Stefano; AGRIFOGLIO, Marco; NOMBELA-FRANCO, Luis; BONAROS, Nikolaos; KASS, Malek; BRUSCHI, Giuseppe; AMABILE, Nicolas; CHHATRIWALLA, Adnan; MESSINA, Antonio; HIRJI, Sameer A.; ANDREAS, Martin; WELSH, Robert; SCHOELS, Wolfgang; HELLIG, Farrel; WINDECKER, Stephan; STORTECKY, Stefan; MAISANO, Francesco; STONE, Gregg W.; DVIR, Danny
    Background: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. Methods: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient >= 10 mm Hg and significant residual mitral regurgitation (MR) as >= moderate. Results: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5 +/- 12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76-996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510-1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR (P<0.001). Mean gradient across the mitral valve postprocedure was 5.7 +/- 2.8 mm Hg (>= 5 mm Hg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients (P=0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P<0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P=0.02). The rates of Mitral Valve Academic Research Consortium-defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P=0.01), mostly related to having postprocedural mean gradient >= 5 mm Hg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74-12.56; P=0.002) and significant residual MR (subhazard ratio, 7.88; 95% CI, 2.88-21.53; P<0.001) were both independently associated with repeat mitral valve replacement. Conclusions: Significant residual MS and/or MR were not infrequent after mitral ViV and ViR procedures and were both associated with a need for repeat valve replacement. Strategies to improve postprocedural hemodynamics in mitral ViV and ViR should be further explored.
  • article 10 Citação(ões) na Scopus
    Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation
    (2023) RHEUDE, Tobias; COSTA, Giuliano; RIBICHINI, Flavio Luciano; PILGRIM, Thomas; AMAT-SANTOS, Ignacio J.; BACKER, Ole De; KIM, Won-Keun; RIBEIRO, Henrique Barbosa; SAIA, Francesco; BUNC, Matjaz; TCHETCHE, Didier; GAROT, Philippe; MYLOTTE, Darren; BURZOTTA, Francesco; WATANABE, Yusuke; BEDOGNI, Francesco; TESORIO, Tullio; TOCCI, Marco; FRANZONE, Anna; VALVO, Roberto; SAVONTAUS, Mikko; WIENEMANN, Hendrik; PORTO, Italo; GANDOLFO, Caterina; IADANZA, Alessandro; BORTONE, Alessandro S.; MACH, Markus; LATIB, Azeem; BIASCO, Luigi; TARAMASSO, Maurizio; ZIMARINO, Marco; TOMII, Daijiro; NUYENS, Philippe; SONDERGAARD, Lars; CAMARA, Sergio F.; PALMERINI, Tullio; ORZALKIEWICZ, Mateusz; STEBLOVNIK, Klemen; DEGRELLE, Bastien; GAUTIER, Alexandre; SOLE, Paolo Alberto Del; MAINARDI, Andrea; PIGHI, Michele; LUNARDI, Mattia; KAWASHIMA, Hideyuki; CRISCIONE, Enrico; CESARIO, Vincenzo; BIANCARI, Fausto; ZANIN, Federico; ESPOSITO, Giovanni; ADAM, Matti; GRUBE, Eberhard; BALDUS, Stephan; MARZO, Vincenzo De; PIREDDA, Elisa; CANNATA, Stefano; IACOVELLI, Fortunato; ANDREAS, Martin; FRITTITTA, Valentina; DIPIETRO, Elena; REDDAVID, Claudia; STRAZZIERI, Orazio; MOTTA, Silvia; ANGELLOTTI, Domenico; SGROI, Carmelo; XHEPA, Erion; KARGOLI, Faraj; TAMBURINO, Corrado; JONER, Michael; BARBANTI, Marco
    Background: The optimal timing to perform percutaneous coronary interventions (PCI) in transcatheter aortic valve implantation (TAVI) patients remains unknown. Aims: We sought to compare different PCI timing strategies in TAVI patients. Methods: The REVASC-TAVI registry is an international registry including patients undergoing TAVI with significant, stable coronary artery disease (CAD) at preprocedural workup. In this analysis, patients scheduled to undergo PCI before, after or concomitantly with TAVI were included. The main endpoints were all-cause death and a composite of all-cause death, stroke, myocardial infarction (MI) or rehospitalisation for congestive heart failure (CHF) at 2 years. Outcomes were adjusted using the inverse probability treatment weighting (IPTW) method. Results: A total of 1,603 patients were included. PCI was performed before, after or concomitantly with TAVI in 65.6% (n=1,052), 9.8% (n=157) or 24.6% (n=394), respectively. At 2 years, all-cause death was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (6.8% vs 20.1% vs 20.6%; p<0.001). Likewise, the composite endpoint was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (17.4% vs 30.4% vs 30.0%; p=0.003). Results were confirmed at landmark analyses considering events from 0 to 30 days and from 31 to 720 days. Conclusions: In patients with severe aortic stenosis and stable coronary artery disease scheduled for TAVI, performance of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies. These results need to be confirmed in randomised clinical trials.
  • article 17 Citação(ões) na Scopus
    Management of Myocardial Revascularization in Patients With Stable Coronary Artery Disease Undergoing Transcatheter Aortic Valve Implantation
    (2022) COSTA, Giuliano; PILGRIM, Thomas; SANTOS, Ignacio J. Amat; BACKER, Ole De; KIM, Won-Keun; RIBEIRO, Henrique Barbosa; SAIA, Francesco; BUNC, Matjaz; TCHETCHE, Didier; GAROT, Philippe; RIBICHINI, Flavio Luciano; MYLOTTE, Darren; BURZOTTA, Francesco; WATANABE, Yusuke; MARCO, Federico De; TESORIO, Tullio; RHEUDE, Tobias; TOCCI, Marco; FRANZONE, Anna; VALVO, Roberto; SAVONTAUS, Mikko; WIENEMANN, Hendrik; PORTO, Italo; GANDOLFO, Caterina; IADANZA, Alessandro; BORTONE, Alessandro Santo; MACH, Markus; LATIB, Azeem; BIASCO, Luigi; TARAMASSO, Maurizio; ZIMARINO, Marco; TOMII, Daijiro; NUYENS, Philippe; SONDERGAARD, Lars; CAMARA, Sergio F.; PALMERINI, Tullio; ORZALKIEWICZ, Mateusz; STEBLOVNIK, Klemen; DEGRELLE, Bastien; GAUTIER, Alexandre; SOLE, Paolo Alberto Del; MAINARDI, Andrea; PIGHI, Michele; LUNARDI, Mattia; KAWASHIMA, Hideyuki; CRISCIONE, Enrico; CESARIO, Vincenzo; BIANCARI, Fausto; ZANIN, Federico; JONER, Michael; ESPOSITO, Giovanni; ADAM, Matti; GRUBE, Eberhard; BALDUS, Stephan; MARZO, Vincenzo De; PIREDDA, Elisa; CANNATA, Stefano; IACOVELLI, Fortunato; ANDREAS, Martin; FRITTITTA, Valentina; DIPIETRO, Elena; REDDAVID, Claudia; STRAZZIERI, Orazio; MOTTA, Silvia; ANGELLOTTI, Domenico; SGROI, Carmelo; KARGOLI, Faraj; TAMBURINO, Corrado; BARBANTI, Marco
    Background:The best management of stable coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI) is still unclear due to the marked inconsistency of the available evidence. Methods:The REVASC-TAVI registry (Management of Myocardial Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation With Coronary Artery Disease) collected data from 30 centers worldwide on patients undergoing TAVI who had significant, stable CAD at preprocedural work-up. For the purposes of this analysis, patients with either complete or incomplete myocardial revascularization were compared in a propensity score matched analysis, to take into account of baseline confounders. The primary and co-primary outcomes were all-cause death and the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure, respectively, at 2 years. Results:Among 2407 patients enrolled, 675 pairs of patients achieving complete or incomplete myocardial revascularization were matched. The primary (21.6% versus 18.2%, hazard ratio, 0.88 [95% CI, 0.66-1.18]; P=0.38) and co-primary composite (29.0% versus 27.1%, hazard ratio, 0.97 [95% CI, 0.76-1.24]; P=0.83) outcome did not differ between patients achieving complete or incomplete myocardial revascularization, respectively. These results were consistent across different prespecified subgroups of patients (< or >75 years of age, Society of Thoracic Surgeons score > or <4%, angina at baseline, diabetes, left ventricular ejection fraction > or <40%, New York Heart Association class I/II or III/IV, renal failure, proximal CAD, multivessel CAD, and left main/proximal anterior descending artery CAD; all P values for interaction >0.10). Conclusions:The present analysis of the REVASC-TAVI registry showed that, among TAVI patients with significant stable CAD found during the TAVI work-up, completeness of myocardial revascularization achieved either staged or concomitantly with TAVI was similar to a strategy of incomplete revascularization in reducing the risk of all cause death, as well as the risk of death, stroke, myocardial infarction, and rehospitalization for heart failure at 2 years, regardless of the clinical and anatomical situations.